https://www.biospace.com/employer/2577520/genscript-probio ProBio en-US Thu, 14 Jul 2022 05:06:07 GMT https://www.biospace.com/genscript-probio-and-daan-bio-therapeutics-sign-a-strategic-cooperation-mou-for-the-discovery-and-development-of-novel-drugs On the July 14, 2022, GenScript ProBio, a global CDMO, and DAAN Bio Therapeutics, an innovative new drug developer such as antibody treatments and cell therapy drugs, announced that they had entered into a strategic cooperation MOU concerning the development for innovation drug discovery & development. Thu, 14 Jul 2022 05:06:07 GMT https://www.biospace.com/genscript-probio-and-daan-bio-therapeutics-sign-a-strategic-cooperation-mou-for-the-discovery-and-development-of-novel-drugs https://www.biospace.com/genscript-probio-and-rvac-medicines-announce-strategic-partnership-for-gmp-plasmid-dna-manufacturing-for-mrna-covid-19-vaccine-candidate GenScript ProBio today announced an agreement to establish a strategic partnership for the manufacturing of GMP-grade plasmid DNA (pDNA) for its mRNA COVID-19 vaccine candidate, RVM-V001, along with collaboration for future therapeutic pipelines. Wed, 22 Feb 2023 13:06:14 GMT https://www.biospace.com/genscript-probio-and-rvac-medicines-announce-strategic-partnership-for-gmp-plasmid-dna-manufacturing-for-mrna-covid-19-vaccine-candidate https://www.biospace.com/genscript-probio-and-comprehensive-cell-solutions-a-business-unit-of-the-new-york-blood-center-enterprises-form-a-pioneering-partnership-to-expedite-cell-and-gene-therapy-development-and-manufacturing GenScript ProBio and Comprehensive Cell Solutions have partnered to spearhead the development of cell and gene therapies, offering a unique and seamlessly integrated solution that spans cell collections and apheresis through cryopreservation of final therapeutics. Wed, 07 Jun 2023 14:36:06 GMT https://www.biospace.com/genscript-probio-and-comprehensive-cell-solutions-a-business-unit-of-the-new-york-blood-center-enterprises-form-a-pioneering-partnership-to-expedite-cell-and-gene-therapy-development-and-manufacturing https://www.biospace.com/genscript-probio-partners-with-nuclixbio-to-pave-the-way-for-south-korea-s-first-large-scale-production-process-for-circular-rna-therapeutics GenScript ProBio and NuclixBio announced on 9th Nov that they have entered into a strategic business agreement to develop the first circular RNA-based anticancer drug in South Korea. Thu, 09 Nov 2023 09:36:05 GMT https://www.biospace.com/genscript-probio-partners-with-nuclixbio-to-pave-the-way-for-south-korea-s-first-large-scale-production-process-for-circular-rna-therapeutics https://www.biospace.com/genscript-probio-signs-viral-vector-manufacturing-mou-with-curocell-for-next-generation-car-t-therapy On November 10, a global multimodality CDMO, GenScript ProBio and specialized CAR-T therapy firm Curocell signed a strategic partnership MOU for the production of viral vectors necessary for the development of next generation of CAR-T therapy, marking another significant step in their ongoing collaboration. Fri, 10 Nov 2023 05:06:09 GMT https://www.biospace.com/genscript-probio-signs-viral-vector-manufacturing-mou-with-curocell-for-next-generation-car-t-therapy https://www.biospace.com/probio-expands-plasmid-dna-and-viral-vector-production-in-new-jersey-to-accelerate-delivery-of-life-changing-cell-and-gene-therapies ProBio Inc, a New Jersey-based contract development and manufacturing organization (CDMO), proudly announce the expansion of its plasmid DNA and viral vector manufacturing capabilities with the opening of a new state-of-the-art facility in Hopewell, New Jersey. Tue, 25 Jun 2024 12:06:11 GMT https://www.biospace.com/probio-expands-plasmid-dna-and-viral-vector-production-in-new-jersey-to-accelerate-delivery-of-life-changing-cell-and-gene-therapies https://www.biospace.com/press-releases/probio-announces-new-executive-appointments Fri, 06 Dec 2024 07:35:04 GMT https://www.biospace.com/press-releases/probio-announces-new-executive-appointments https://www.biospace.com/press-releases/probio-to-present-data-on-its-cd3-agonistic-single-domain-antibody-platform-for-accelerated-development-of-t-cell-engager-multi-specific-antibodies Mon, 14 Apr 2025 14:35:38 GMT https://www.biospace.com/press-releases/probio-to-present-data-on-its-cd3-agonistic-single-domain-antibody-platform-for-accelerated-development-of-t-cell-engager-multi-specific-antibodies https://www.biospace.com/press-releases/probio-announces-six-presentations-at-american-society-of-gene-and-cell-therapy-28th-annual-meeting-2025 Wed, 23 Apr 2025 10:53:49 GMT https://www.biospace.com/press-releases/probio-announces-six-presentations-at-american-society-of-gene-and-cell-therapy-28th-annual-meeting-2025 https://www.biospace.com/press-releases/probio-opens-flagship-u-s-plasmid-viral-vector-manufacturing-facility-in-hopewell-new-jersey-to-advance-cell-and-gene-therapy Mon, 30 Jun 2025 05:30:04 GMT https://www.biospace.com/press-releases/probio-opens-flagship-u-s-plasmid-viral-vector-manufacturing-facility-in-hopewell-new-jersey-to-advance-cell-and-gene-therapy